26 March 2021
EMA/PDCO/193094/2021
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 23-26 March 2021

Chair: Koenraad Norga – Vice-Chair: Sabine Scherer

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Due to restricted involvement, the Chair Koenraad Norga was replaced by the Vice-chair Sabine Scherer for the voting on agenda topic 2.3.18 and 2.3.21.

1.2. Adoption of agenda

PDCO agenda for 23-26 March 2021

The agenda for 23-26 March 2021 meeting was adopted.

1.3. Adoption of the minutes

PDCO minutes for 23-26 February 2021

The minutes for 23-26 February 2021 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. RAAV8 viral vector encoding the human UGT1A1 transgene (rAAV8-hUGT1A1) - Orphan - EMEA-002021-PIP01-16

GENETHON; Treatment of Crigler-Najjar syndrome

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant to the request for modification, the PDCO adopted a positive opinion for the PIP with a deferral for the proposed medicine, for children and adolescents from 28 days to less than 18 years of age, in the condition of treatment of Crigler-Najjar syndrome. A waiver on the grounds "disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets" was adopted for preterm and term newborn infants from birth to less than 28 days of age.

2.1.2. Vedolizumab - EMEA-000645-PIP04-20

Takeda Pharma A/S; Treatment of pouchitis

Day 120 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

In a written response the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 2 years to less than 18 years of age in the condition of treatment of pouchitis was adopted. A waiver was granted for the paediatric population from birth to less than 2 years of age on the grounds that the condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). The PDCO granted a deferral for the completion of this PIP.

2.1.3. Pegfilgrastim - EMEA-002671-PIP02-20

Accord Healthcare S.L.U.; Prevention of chemotherapy-induced febrile neutropenia / Treatment of chemotherapy-induced neutropenia

Day 120 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant a positive opinion for the PIP for pegfilgrastim (recombinant human granulocyte colony stimulating factor coupled with recombinant human albumin fusion protein) including

all subsets of the paediatric population (0 to 18 years of age) in the conditions of treatment of chemotherapy-induced neutropenia and prevention of chemotherapy-induced febrile neutropenia was adopted.

2.1.4. Human anti-interleukin-15 (IL-15) monoclonal antibody - EMEA-002775-PIP01-20

Provention Bio, Inc.; Treatment of coeliac disease

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agreed with the applicant's request for a waiver following the responses to the request for modification. The PDCO recommended granting a waiver for the proposed product for all subsets of the paediatric population (0 to 18 years of age) in the condition treatment of coeliac disease on the grounds "lack of significant therapeutic benefit over existing treatments for paediatric patients".

2.1.5. Edaravone - Orphan - EMEA-002785-PIP01-20

Treeway B.V.; Treatment of amyotrophic lateral sclerosis

Day 120 opinion

Neurology

Summary of Committee discussion:

The PDCO recommended granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition treatment of amyotrophic lateral sclerosis (ALS) on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible. The Norwegian PDCO member was in agreement. The committee stressed that while it was not deemed feasible to generate all the data necessary for a stand-alone benefit/risk assessment for a paediatric indication for this product in the context of a PIP as this population is very rare and extrapolation is not feasible, it was still deemed important to generate as much data as possible in the paediatric population for this rare disease where an unmet need for effective and safe treatments exists. To this end, it was mentioned that inclusion of paediatric patients via a Compassionate Use Programme or in adult studies may also represent a way forward to generate data for the treatment of paediatric patients with ALS.

2.1.6. Respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF) - EMEA-002795-PIP01-20

Pfizer Europe MA EEIG; Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation

Day 120 opinion

Vaccines

Summary of Committee discussion:

In the written response, provided before the Committee plenary, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF) for females from menarche to less than 18 years of age, in the condition of prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation was adopted.
The PDCO agreed on a waiver in males from birth to less than 18 years of age and females from birth to before menarche on the grounds of the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).
The PDCO granted a deferral for the completion of this PIP.

2.1.7. (S)-N-(1-amino-4-(dimethylamino)-1-oxobutan-2-yl)-5-(2,4-difluorophenoxy)-1-isobutyl-1H-indazole-6-carboxamide - EMEA-002948-PIP01-20

Pfizer Europe MA EEIG; Treatment of dilated cardiomyopathy due to lamin A/C gene mutations

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of dilated cardiomyopathy due to lamin A/C gene mutations" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible. The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition. The Norwegian PDCO member was in agreement.

2.1.8. Anti-CD40L humanized monoclonal antibody (SAR441344) - EMEA-002945-PIP01-20

Sanofi-aventis recherche & développement; Treatment of Sjogren's Syndrome

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of Treatment of Sjogren's Syndrome on the grounds of lack of significant

therapeutic benefit as clinical studies are not feasible.

2.1.9. Reparixin - Orphan - EMEA-001693-PIP02-20

Dompé farmaceutici S.p.A.; Treatment of coronavirus disease 2019 (COVID-2019)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee the PDCO disagrees with the applicant's request for a waiver for reparixin for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of coronavirus disease 2019 (COVID-2019)". The committee adopted a negative opinion, refusing the full waiver request for all paediatric age subsets in the condition "treatment of coronavirus disease 2019 (COVID-2019)".

2.1.10. (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide - EMEA-002943-PIP01-20

Eli Lilly and Company; Treatment of mature B-cell malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed this procedure at D60 during the March 2021 plenary meeting. The PDCO confirmed all the conclusions reached at Day 30 and decided that the waiver should be agreed on the grounds that LOXO-305 is likely to be ineffective in the paediatric population.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of mature B-cell malignancies" on the grounds that the specific medicinal product is likely to be ineffective in the paediatric population.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Pembrolizumab / quavonlimab - EMEA-002949-PIP01-20

Merck, Sharp & Dohme (Europe) Inc; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue and melanoma)

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed this procedure at D60 during the March 2021 plenary meeting. The PDCO adopted a positive opinion on a product specific waiver for quavonlimab / pembrolizumab for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions "treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue neoplasms and melanoma)" and "treatment of malignant neoplasms of the central nervous system" on the grounds that the product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Simoctocog alfa - EMEA-C-001024-PIP01-10-M02

Octapharma Pharmazeutika Produktionsges.m.b.H.; Treatment of hereditary factor VIII deficiency / Haemophilia A

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001024-PIP01-M01

The PDCO adopted on 26 March 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0014/2020) of 6 January 2020.

2.2.2. Lenvatinib - EMEA-C3-001119-PIP02-12-M07

Eisai GmbH; Treatment of papillary thyroid cancer

Day 30 letter

Oncology

Summary of Committee discussion:

The PDCO discussed the completed studies, study 4 (Pharmacology study of lenvatinib in combination with ifosfamide and etoposide in paediatric tumour models), study 5 (Open-label, multi-centre, non-controlled trial to evaluate pharmacokinetics, pharmacodynamics, tolerability and safety of lenvatinib in children from 2 years to less than 18 years of age with

a relapsed or refractory solid malignant tumour and, in patients with osteosarcoma, an extension phase to evaluate lenvatinib in combination with ifosfamide and etoposide) and study 7 (Population PK analysis to establish the dose-response relationship of lenvatinib in paediatric patients with differentiated thyroid cancer (DTC) and to support extrapolation of efficacy from adult patients to paediatric patients with DTC) taking into account feedback provided by the applicant and considered that these are compliant with the latest Agency's Decision P/0427/2020. The PDCO concluded positively on this partial compliance check.

2.2.3. Teduglutide - EMEA-C-000482-PIP01-08-M06

Takeda Pharmaceuticals International AG; Treatment of short bowel syndrome

Day 30 discussion

Gastroenterology-Hepatology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- C1-000482-PIP01-08-M02

The PDCO adopted on 26 March 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0479/2020) of 1 December2020.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Pegcetacoplan - Orphan - EMEA-002600-PIP01-19-M01

Apellis Ireland Limited; Treatment of paroxysmal nocturnal haemoglobinuria

Day 60 opinion

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0149/2020 of 17 April 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Remimazolam (as besylate) - EMEA-001880-PIP02-19-M02

PAION Deutschland GmbH; Sedation / General anaesthesia

Day 60 opinion

Anaesthesiology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0364/2019 of 04 November 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Ticagrelor - EMEA-000480-PIP01-08-M14

AstraZeneca AB; Prevention of thromboembolic events

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO re-discussed this procedure at D60 during the March 2021 plenary meeting and confirmed all the conclusions reached at Day 30.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0017/2020 of 17 June 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Spesolimab - EMEA-002475-PIP02-19-M01

Boehringer Ingelheim International GmbH; Treatment of Generalized Pustular Psoriasis / Prevention of Generalized Pustular Psoriasis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0195/2020 issued on 15 May 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Cipaglucosidase alfa - Orphan - EMEA-002447-PIP01-18-M01

Amicus Therapeutics Europe Limited; Treatment of glycogen storage disease Type II (Pompe's disease)

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0474/2020 of 1 December 2020).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Pegunigalsidase alfa - Orphan - EMEA-001828-PIP01-15-M02

Chiesi Farmaceutici S.p.A.; Treatment of Fabry disease

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0286/2018 issued on 12 September 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Avacopan - Orphan - EMEA-002023-PIP01-16-M05

ChemoCentryx Ireland Ltd.; Treatment of ANCA-associated vasculitis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0103/2020 of 20 March 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Doravirine - EMEA-001676-PIP01-14-M04

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus type 1 (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0254/2020 of 15/7/2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Rilpivirine / Dolutegravir - EMEA-001750-PIP01-15-M04

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

In March 2021 the PDCO confirmed the position already agreed at D30.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0359/2020 of 9/9/2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Tenofovir alafenamide / emtricitabine / cobicistat / darunavir - EMEA-001825-PIP01-15-M03

Janssen-Cilag International NV; Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

In March 2021 the PDCO confirmed the conclusion already reached at D30.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0253/2017 of 4/9/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Tenofovir disoproxil fumarate / lamivudine / doravirine - EMEA-001695-PIP01-14-M04

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus-1 (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0253/2020 of 15/7/2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. Ataluren - Orphan - EMEA-000115-PIP01-07-M11

PTC Therapeutics International, Limited; Treatment of dystrophinopathy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0335/2019 of 11 September 2019).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Brivaracetam - Orphan - EMEA-000332-PIP01-08-M16

UCB Pharma S.A.; Treatment of epilepsy with partial onset seizures

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0324/2020 of 12 August 2020). The Norwegian PDCO member was in agreement.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Brivaracetam - Orphan - EMEA-000332-PIP02-17-M02

UCB Pharma S.A.; Treatment of paediatric epilepsy syndromes / Treatment of neonatal seizures

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0203/2020 of 12 June 2020). The Norwegian PDCO member was in agreement.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Bumetanide - EMEA-001303-PIP01-12-M03

Les Laboratoires Servier; Autism Spectrum Disorder

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0340/2017 of 10 November 2017.

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Ganaxolone - Orphan - EMEA-002341-PIP01-18-M01

Marinus Pharmaceuticals Inc.; Treatment of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Day 60 opinion

Neurology

Summary of Committee discussion:

In March 2021 the PDCO discussed the responses received by the applicant to the issues raised at D30.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0361/2019 of 4/11/2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Dostarlimab - EMEA-002463-PIP01-18-M01

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies).

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0303/2019 of 10 September 2019). The Norwegian PDCO member was in agreement.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Isatuximab - EMEA-002205-PIP01-17-M02

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0193/2019 of 13 May 2019).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.19. Lenvatinib - EMEA-001119-PIP03-19-M01

Eisai GmbH; Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0210/2020 of 16 June 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.20. Niraparib (as tosylate monohydrate) - Orphan - EMEA-002268-PIP02-18-M01

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies).

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0313/2019 of 10 September 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.21. Obinutuzumab - Orphan - EMEA-001207-PIP01-11-M01

Roche Registration GmbH; Treatment of acute lymphoblastic leukaemia / Treatment of mature B-cell lymphoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed this procedure at D60 during the March 2021 plenary meeting and confirmed all the conclusions reached at Day 30.
Based on the review of the documentation submitted by the applicant, the PDCO considered that the proposed changes could be acceptable and granted a product specific waiver for

this product on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0046/2013 of 1 March 2013).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Ruxolitinib (phosphate) - EMEA-000901-PIP03-16-M02

Novartis Europharm Limited; Treatment of acute Graft versus Host Disease (aGvHD)

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0190/2019 of 15 May 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.23. Concentrate of proteolytic enzyme enriched in bromelain - Orphan - EMEA-000142-PIP02-09-M11

MediWound Germany GmbH; Treatment of burns

Day 60 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes and timelines could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0430/2020 of 5 November 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
The committee noted the agreement by the applicant on the outstanding issues raised by the PDCO during the D30 discussion. Overall, all issues were considered adequately addressed.

2.3.24. Meloxicam / Bupivacaine - EMEA-002246-PIP01-17-M02

Heron Therapeutics B.V.; Treatment of acute postoperative pain

Day 60 opinion

Pain

Summary of Committee discussion:

The PDCO's view expressed at D30 was re-discussed and endorsed.

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0088/2020 of 18 March 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.25. Birch pollen extract (Betula verrucosa) - EMEA-001879-PIP01-15-M03

ALK-Abelló A/S; Treatment of allergic rhinitis / rhino-conjunctivitis

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0434/2020 of 6 November 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.26. Brexpiprazole - EMEA-001185-PIP01-11-M07

Otsuka Pharmaceutical Development & Commercialisation Europe GmbH; Treatment of schizophrenia

Day 60 opinion

Psychiatry

Summary of Committee discussion:

Responses to the PDCO's Day 30 comments were received from the applicant.
Consequently, the proportion of EU patients was maintained, and the extension of timelines reduced.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0316/2018 of 12 September 2018.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

2.6.1. Oxygen / Argon - EMEA-002921-PIP01-20

Air Liquide Santé International; Treatment of acute ischaemic stroke

Correction of Opinion

Article 7; Waiver

Neurology

Summary of Committee discussion:

A correction was adopted for the wording of the condition.

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Brentuximab vedotin - EMEA-C5-000980-PIP01-10-M07

Takeda Pharma A/S; Treatment of Hodgkin lymphoma

Day 1 letter

Oncology

2.7.2. Baloxavir marboxil - EMEA-C2-002440-PIP01-18-M01

Roche Registration GmbH; Treatment of influenza

Day 30 letter

Infectious Diseases

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. EMEA-002735-PIP01-19

Cardioplegia

Day 90 discussion

Cardiovascular Diseases

3.1.2. Sotatercept - EMEA-002756-PIP01-19

Pulmonary arterial hypertension

Day 90 discussion

Cardiovascular Diseases

3.1.3. Human plasma derived c1-inhibitor - EMEA-002818-PIP01-20

Pre-procedure prevention of acute hereditary angioedema (HAE) / Treatment of hereditary angioedema / Treatment of hereditary angioedema (HAE)

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.4. Iscalimab - EMEA-002842-PIP01-20

Prophylaxis against transplant rejection / Prophylaxis of solid organ transplant rejection

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.5. Ravulizumab - EMEA-001943-PIP03-20

Treatment of myasthenia gravis

Day 90 discussion

Neurology

3.1.6. Erdafitinib - EMEA-002042-PIP02-20

Treatment of all conditions included in the category of malignant neoplasms (except urothelial carcinoma, haematopoietic and lymphoid tissue neoplasms)

Day 90 discussion

Oncology

3.1.7. Talazoparib - EMEA-002066-PIP01-20

Treatment of Ewing sarcoma

Day 90 discussion

Oncology

3.1.8. Atropine - EMEA-002744-PIP01-19

Treatment of Myopia

Day 90 discussion

Ophthalmology

3.1.9. Recombinant protein derived from the SARS CoV2 prefusion Spike delta TM protein adjuvanted with AS03 - EMEA-002915-PIP01-20

Prevention of Covid-19

Day 90 discussion

Vaccines

3.1.10. EMEA-002735-PIP03-20

Heart transplantation

Day 60 discussion

Cardiovascular Diseases

3.1.11. EMEA-002944-PIP01-20

Treatment of Type 2 Diabetes Mellitus

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.12. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP01-20

Treatment of non-alcoholic steatohepatitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.13. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP02-20

Treatment of obesity

Day 60 discussion

Gastroenterology-Hepatology

3.1.14. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP03-20

Catalyst Biosciences, Inc.; Treatment of haemophilia A

Day 60 discussion

Haematology-Hemostaseology

3.1.15. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP04-20

Catalyst Biosciences, Inc.; Treatment of haemophilia B

Day 60 discussion

Haematology-Hemostaseology

3.1.16. Baricitinib - EMEA-001220-PIP08-20

Treatment of alopecia areata

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.17. Exebacase - EMEA-002947-PIP01-20

Treatment of *Staphylococcus aureus* blood stream infections (bacteraemia)

Day 60 discussion

Infectious Diseases

3.1.18. Regdanvimab - EMEA-002961-PIP01-21

Treatment of Coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.19. EMEA-002964-PIP01-21

Prophylaxis of SARS-CoV-2 infection / Treatment and decreased transmission of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.20. EMEA-002965-PIP01-21

Prophylaxis of SARS-CoV-2 infection / Treatment and decreased transmission of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.21. EMEA-002984-PIP01-21

Treatment of onychomycosis

Day 60 discussion

Infectious Diseases

3.1.22. Lutetium (^{177}Lu) oxodotreotide - Orphan - EMEA-002950-PIP01-20

Advanced Accelerator Applications; Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Day 60 discussion

Oncology

3.1.23. Apitegromab - Orphan - EMEA-002951-PIP01-20

Scholar Rock, Inc.; Spinal muscular atrophy

Day 60 discussion

Other / Neurology

3.1.24. EMEA-002946-PIP01-20

Treatment of Major Depressive Disorder (MDD)

Day 60 discussion

Psychiatry

3.1.25. EMEA-002958-PIP01-21

Treatment of hypertrophic cardiomyopathy

Day 30 discussion

Cardiovascular Diseases

3.1.26. EMEA-002962-PIP01-21

Treatment of elevated cholesterol

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.27. Drospirenone - EMEA-001495-PIP02-21

Treatment of endometriosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.28. Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) - Orphan - EMEA-002955-PIP01-21

Ascendis Pharma Bone Diseases A/S; Treatment of hypoparathyroidism

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.29. Tildacerfont - Orphan - EMEA-002970-PIP01-21

Spruce Biosciences, Inc.; Treatment of congenital adrenal hyperplasia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.30. Nangibotide - EMEA-002953-PIP01-21

Treatment of septic shock

Day 30 discussion

Infectious Diseases

3.1.31. Tosatoxumab - Orphan - EMEA-002506-PIP03-21

Aridis Pharmaceuticals Inc; Treatment of *Staphylococcus aureus* pneumonia

Day 30 discussion

Infectious Diseases / Pneumology - Allergology

3.1.32. Naproxen sodium / Sumatriptan - EMEA-002959-PIP01-21

Acute treatment of migraine attacks

Day 30 discussion

Neurology

3.1.33. Savolitinib - EMEA-002627-PIP02-21

Treatment of malignant renal neoplasms

Day 30 discussion

Oncology

3.1.34. Synthetic hypericin - Orphan - EMEA-002956-PIP01-21

Soligenix NL B.V; Cutaneous T-Cell Lymphoma

Day 30 discussion

Oncology

3.1.35. EMEA-002895-PIP02-21

Treatment of macular oedema due to central or tributary (branch) retinal vein occlusion / Treatment of diabetic retinopathy / Treatment of retinopathy of prematurity / Treatment of choroidal neovascularisation

Day 30 discussion

Ophthalmology

3.1.36. Human SARS-CoV-2 immunoglobulin - EMEA-002911-PIP01-20

Treatment of hospitalised patients with COVID-19 disease / Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Other

3.1.37. Human SARS-CoV-2 immunoglobulin - EMEA-002912-PIP01-20

Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Other

3.1.38. Zorecimeran - EMEA-002986-PIP01-21

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines / Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Afatinib - EMEA-C-001596-PIP02-17-M02

Boehringer Ingelheim International GmbH; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue neoplasms)

Day 30 discussion

Oncology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Liquid ethalonic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M05

LEGACY HEALHCARE; Treatment of alopecia

Day 30 discussion

Dermatology

3.3.2. Denosumab - EMEA-000145-PIP02-12-M04

Amgen Europe B.V.; Treatment of Osteoporosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.3. Sotagliflozin - EMEA-001517-PIP02-14-M03

Guidehouse Germany GmbH; Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Linaclotide - EMEA-000927-PIP01-10-M06

Allergan Pharmaceuticals International Limited; Treatment of Functional Constipation

Day 30 discussion

Gastroenterology-Hepatology

3.3.5. Betibeglogene autotemcel - Orphan - EMEA-001665-PIP01-14-M05

bluebird bio (Netherlands) B.V.; Treatment of β-thalassaemia

Day 30 discussion

Haematology-Hemostaseology

3.3.6. Setmelanotide - Orphan - EMEA-002209-PIP01-17-M02

Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders

Day 30 discussion

Nutrition

3.3.7. Venetoclax - Orphan - EMEA-002018-PIP02-16-M04

AbbVie Ltd; Treatment of haematopoietic and lymphoid malignant neoplasms / Treatment of solid tumour malignant neoplasms

Day 30 discussion

Oncology / Haematology-Hemostaseology

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 23 March 2021 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. Semaglutide - EMEA-01-2021

Novo Nordisk; All classes of medicinal products for treatment of Alzheimer's disease / Treatment of mild cognitive impairment and mild dementia, both of the Alzheimer's type

Summary of Committee discussion:

The applicability of the class waiver as referred to in the EMA decision CW/0001/2015 to the planned therapeutic indication(s) was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: the PDCO took note of PIPs already agreed for the medicinal product (solution for injection and/or tablet) for the conditions 'treatment of type 2 diabetes mellitus' and 'treatment of obesity'.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No item

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

No item

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

Pauliina Lehtolainen Dalkilic has been appointed member and Anne Paavola as alternate to the PDCO from Finland.

9.1.1. Roll-out of WebEx to PDCO / EMA

Summary of Committee discussion:

The Committee was informed on the new platform for virtual meetings.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in February 2021, was presented to the PDCO members.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The chair of the Non-clinical Working Group (NcWG) identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.4.2. Feedback from EMA/EUnetHTA meeting on extrapolation

Action: For discussion

Summary of Committee discussion:

The PDCO was informed about the conclusions and next steps from a technical workshop which took place between EMA and EUnetHTA intended to foster mutual understanding of the application of extrapolation in the paediatric population.

9.5. Cooperation with International Regulators

9.5.1. Paediatric oncology common commentary

Summary of Committee discussion:

The PDCO adopted a common commentary on paediatric oncology drug development developed jointly with the FDA.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No item

9.8. Planning and reporting

No item

10. Any other business

10.1. COVID -19 update

Summary of Committee discussion:

The PDCO was informed of the latest updates on COVID vaccines and therapeutics, with special attention to those aspects relevant to paediatrics.

10.2. Re-engineered ITF

Summary of Committee discussion:

The Committee was informed of the ITF activities, early interaction with stakeholders and upcoming meetings.

10.3. Update on CONSIGN project - EMA draft pregnancy strategy

Summary of Committee discussion:

An update was provided on the CONSIGN project (COVID 19 infection and medicines in pregnancy) and on international collaboration activities.

10.4. EMA Business Pipeline activity and Horizon scanning

Summary of Committee discussion:

The business pipeline report for Q1/2021 was provided for information.

10.5. Update on the Eudra mailbox

Summary of Committee discussion:

A status report was provided to the Committee on the implementation of a Eudra mailbox.

11. Breakout sessions

11.1. Paediatric oncology

Summary of Committee discussion:

The group discussed topics related to Paediatric Investigation Plans recently submitted to the PDCO.

11.2. Neonatology

Summary of Committee discussion:

The breakout session was cancelled.

11.3. Update on the Revision of the Regulation

Summary of Committee discussion:

The PDCO discussed topics relating to the revision of the paediatric regulation.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 23-26 March 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Koenraad Norga	Chair	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	2.3.18. Dostarlimab - EMEA-002463-PIP01-18-M01 2.3.21. Niraparib (as tosylate monohydrate) - Orphan - EMEA-002268-PIP02-18-M01
Johanna Wernsperger	Alternate	Austria	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Karen Van Malderen	Alternate	Belgium	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on:	2.3.23. Ruxolitinib phosphate - EMEA-000901-PIP03-16-M02
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Georgios Savva	Member	Cyprus	No interests declared	
Lucie Kravackova	Member	Czechia	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Anastasia	Alternate	Greece	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Mountaki				
Eleni Katsomiti	Member	Greece	No interests declared	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Fabio Midulla	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Dovile Zacharkiene	Member	Lithuania	No interests declared	
Silvijus Abramaviciu s	Alternate	Lithuania	No restrictions applicable to this meeting	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Jaroslav Sterba	Member	Patients' Organisation Representative	No interests declared	
Michal Odermarsky	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Member	Sweden	No interests declared	
Sara Vennberg	Alternate	Sweden	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Lutz Wiesner	Expert - via telephone*	Germany	No interests declared	
Gaby Lydia Wangorsch	Expert - via telephone*	Germany - PEI	No interests declared	
Emmely de Vries	Expert - via telephone*	Netherlands - CBG/MEB	No interests declared	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Mårten Wendt	Expert - via telephone*	Sweden -MPA	No interests declared	
A representative from the European Commission attended the meeting Meeting run with support from relevant EMA staff				
* Experts were only evaluated against the agenda topics or activities they participated in				

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/